Laura is the vice president of content of Managed Healthcare Executive® (MHE) and all its brands, including Formulary Watch® and Chief Healthcare Executive®. She has been working on MHE since 2019 and has been with MHE's parent company, MJH Life Sciences®, since 2011. She has an MA in business and economic reporting from New York University.
You can reach her at ljoszt@mjhlifesciences.com or you can connect with her on LinkedIn or Twitter.
Management of EoE May Need to Be Rethought to Reduce Treatment Burden, Impact on Quality of Life
September 2nd 2022Therapeutic goals of reducing eosinophil counts below a certain level in eosinophilic esophagitis (EoE) has a marginal benefit for the impact on quality of life and treatment burden.
Read More
There Remains an Unmet Need for EoE Treatments That Provide Effective, Long-term Disease Control
May 5th 2022Patients with eosinophilic esophagitis (EoE) are faced with delayed diagnosis, burdens related to symptoms, quality of life and cost, but lack targeted systemic therapies to improve long-term disease control.
Read More
Researchers Compare Correlation of Two PROMs With Type 2 Inflammatory Mediators
May 1st 2022In patients with chronic rhinosinusitis with nasal polyps, the 12-item Patient Reported Outcomes in Chronic Rhinosinusitis had a stronger correlation with type 2 inflammatory biomarkers than a more widely used measure.
Read More
Tezspire Misses Primary End Point in SOURCE, but Provides Other Benefits for Patients With Asthma
April 22nd 2022Despite missing the primary end point of significantly reducing oral corticosteroid dose, patients with asthma on Tezspire in the SOURCE trial received other benefits from the drug.
Read More
Identifying Disparities in Treatment and Quality of Care Team Relationships for Patients With Asthma
March 15th 2022Research presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting found minority patients with asthma perceived lower quality interactions with their care team, but did not find significant differences in the prescription of biologic medications across racial/ethnic groups.
Read More
Employers Face Barriers With Adopting Biosimilars
March 1st 2022Despite the promise of savings billions of dollars in the United States, adoption of biosimilars has been slow. A roundtable discussion among employers highlighted some of the barriers, including formulary design and drug pricing and rebates.
Read More
Canadian Study Highlights Low Uptake of Systemic Therapy in HCC Despite the Benefits
January 28th 2022Although systemic therapy improves survival for patients with advanced unresectable hepatocellular carcinoma (HCC), uptake was low and dose reductions were common, according to a real-world Canadian study.
Read More